Press Releases

MENLO PARK, Calif. , Aug. 5, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California .     PacBio's management is scheduled to participate in a fireside chat on Thursday,

MENLO PARK, Calif. , Aug. 3, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022 .     Second quarter results Revenue of $35.5 million , a 16% increase compared with $30.6 million in the prior year period.

MENLO PARK, Calif. , July 21, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Jeff Eidel as Chief Commercial Officer, effective August 16, 2022 . In this role, Mr.

MENLO PARK, Calif. , July 18, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2022 financial results on Wednesday, August 3, 2022 , at 5:00 pm Eastern Time .     The call will be webcast live and may be

MENLO PARK, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of

Advanced Automation Aims to Optimize Service Lab Efficiency and Highly Reproducible Data Production from HiFi Long-Read Sequencing MENLO PARK, Calif., TOKYO, May 09, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today

MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. PacBio’s management is scheduled to present on Thursday, May 12 at 11:20 a.m. Pacific Time / 2:20 p.m.

MENLO PARK, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results Revenue of $33.2 million, a 14% increase compared with $29.0 million in the prior year period.

MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, to use the

Significant enhancements to the Sequel II/IIe platform include methylation calling in native DNA, greatly accelerated sample preparation, and support for gene therapy applications MENLO PARK, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality,